SPOTLIGHT: Hana expects delay

Manufacturing problems are delaying development of Hana Bioscience's Zensana, an oral spray for treating nausea prompted by chemotherapy, radiation and cancer surgery. "Precipitated" material was found in batches of the drug, which may force Hana to change the way it is formulated. The snafu will lead to a delay in the FDA's approval of Zensana, said CEO Mark Ahn, who added that Hana is still completely committed to the therapy. Release | Report